ArticleBMC cancer2024

Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.

Armando Santoro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.